Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 4
1967 1
1968 2
1969 5
1970 1
1971 1
1972 1
1973 3
1974 1
1975 4
1976 1
1977 7
1978 3
1979 4
1980 1
1981 4
1982 2
1984 1
1985 2
1986 3
1987 1
1988 1
1989 5
1990 3
1991 1
1993 1
1995 3
1996 1
1997 2
1998 1
1999 1
2000 1
2001 2
2002 1
2005 1
2010 1
2013 1
2014 2
2016 2
2017 2
2018 2
2019 2
2020 1
2021 1
2022 4
2023 4
2024 5
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Maurer MS, et al. N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757. N Engl J Med. 2023. PMID: 37888916 Free PMC article. Clinical Trial.
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, Pagliaro Rocha TM, Shankarappa VB, Terauchi Y, Ji L. Mathieu C, et al. Among authors: larsen jh. Lancet Diabetes Endocrinol. 2025 Jul;13(7):568-579. doi: 10.1016/S2213-8587(25)00096-8. Epub 2025 Jun 4. Lancet Diabetes Endocrinol. 2025. PMID: 40482671 Clinical Trial.
Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosis.
Larsen JH, Hegelund JS, Pedersen MK, Andersson CM, Lindegaard CA, Hansen DR, Stubbe J, Lindholt JS, Hansen CS, Grentzmann A, Bloksgaard M, Jensen BL, Rodriguez-Díez RR, Ruiz-Ortega M, Albinsson S, Pasterkamp G, Mokry M, Leask A, Goldschmeding R, Pilecki B, Sorensen GL, Pyke C, Overgaard M, Beck HC, Ketelhuth DFJ, Rasmussen LM, Steffensen LB. Larsen JH, et al. Cardiovasc Res. 2024 Dec 4;120(15):1851-1868. doi: 10.1093/cvr/cvae174. Cardiovasc Res. 2024. PMID: 39167826 Free PMC article.
Author's response.
Larsen JH. Larsen JH. Br J Gen Pract. 2014 May;64(622):220-1. doi: 10.3399/bjgp14X679598. Br J Gen Pract. 2014. PMID: 24771814 Free PMC article. No abstract available.
[Supervision--why?].
Larsen JH, Nystrup J, Risør O, Malmstrøm L. Larsen JH, et al. Ugeskr Laeger. 2005 Sep 19;167(38):3578-80. Ugeskr Laeger. 2005. PMID: 16219185 Danish.
Tamoxifen-independent Cre-activity in SMMHC-CreER T2 mice.
Steffensen LB, Stubbe J, Overgaard M, Larsen JH. Steffensen LB, et al. Among authors: larsen jh. Atheroscler Plus. 2022 Jan 31;48:8-11. doi: 10.1016/j.athplu.2022.01.002. eCollection 2022 Apr. Atheroscler Plus. 2022. PMID: 36644559 Free PMC article.
Kawasaki disease--a yersiniosis?
Larsen JH. Larsen JH. J Infect Dis. 1989 Nov;160(5):900-1. doi: 10.1093/infdis/160.5.900. J Infect Dis. 1989. PMID: 2809262 No abstract available.
[Clinical immunology].
Larsen JH. Larsen JH. Ugeskr Laeger. 1975 May 12;137(20):1129-31. Ugeskr Laeger. 1975. PMID: 1136005 Danish. No abstract available.
106 results